ACTG A5201 ATAZANAVIR/RITONAVIR AFTER SUSTAINED VIROLOGIC SUPPRESSION

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究的主要目的是评估单独接受利托那韦增强阿扎那韦（ATV/RTV）维持治疗24周后患者病毒学失败的风险。病毒学失败定义为连续2次血浆HIV-1 RNA检测达到200拷贝/mL。HIV-1 RNA测量值为>200拷贝/mL的受试者必须在30天内返回以确认病毒学失败，此时，如果第二病毒载量为>1000拷贝/mL，则将进行实时基因分型。关于未来抗逆转录病毒治疗的决定将根据目前的临床指南作出，可能包括恢复以前的联合治疗。所有在第2步永久停止研究治疗的受试者，包括因病毒学失败而改变治疗的受试者，将在研究中随访治疗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary purpose of this study is to evaluate the risk of virologic failure in subjects 24 weeks after treatment with ritonavir-boosted atazanavir (ATV/RTV) maintenance therapy alone. Virologic failure is defined as 2 consecutive plasma HIV-1 RNA measurements >200 copies/mL. Subjects with HIV-1 RNA measurements >200 copies mL must return within 30 days for confirmation of virologic failure, at which point real-time genotyping will be performed if the second viral load is >1000 copies/mL. Decisions about future antiretroviral therapy will be made according to current clinical guidelines and may include resumption of previous combination therapy. All subjects who permanently discontinue study treatment on Step 2, including those who change therapy due to virologic failure, will be followed off treatment on study.